TransCode Acquires Polynoma From CK Life Sciences

October 08, 2025 — 08:24 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma.

Concurrent with the acquisition, TransCode announced a $25 million investment from CK Life Sciences Int'l. to be used primarily to advance clinical development of TransCode's lead microRNA asset, TTX-MC138, into a Phase 2 clinical trial.

Philippe Calais, has been appointed as TransCode's CEO and remains Chairman of the Board, but has stepped down from his positions on the Board's Audit Committee and Compensation Committee. Tom Fitzgerald steps down as Interim CEO but remains CFO and a member of the Board.

For More Such Health News, visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

TransCode Acquires Polynoma From CK Life Sciences

Tags

Latest Articles